Supernus Pharmaceuticals reported robust third-quarter results, driven by strong performances from key growth products including Onapgo, Qelbree, GOCOVRI, and collaboration revenues from Zurzuvae.

• Total revenue reached $192.1 million, a 9.5% increase year-over-year, driven by a significant uptick in net product sales.
• Onapgo's net sales soared to $6.8 million, up from $1.6 million in Q2, highlighting strong initial demand amid supply constraints.
• Collaboration revenue from Zurzuvae accounted for $20.2 million, showing a 150% increase year-over-year since the acquisition of Sage.
• Qelbree and GOCOVRI reported net sales growth of 31% and 15%, respectively, reflecting strong market demand in both pediatric and adult segments.
• The company expects to achieve annual synergies of up to $200 million from the Sage acquisition by mid-2026.